Telix制药公司在2025年H1收入猛增63%,尽管损失不大,但仍大量投资于研发。 Telix Pharmaceuticals saw a 63% revenue surge in H1 2025, investing heavily in R&D despite a small loss.

Telix制药公司报告说,2025年上半年,收入猛增63%,达到3.904亿美元,重点是通过增加研发支出实现长期增长,增长47%,达到8,160万美元。 Telix Pharmaceuticals reported a 63% jump in revenue to $390.4 million for the first half of 2025, with a focus on long-term growth through increased R&D spending, up 47% to $81.6 million. 尽管税前损失了480万美元,但Telix的精密医学部门的收入增加了30%。 Despite a loss before tax of $4.8 million, Telix's Precision Medicine segment saw a 30% revenue increase. 该公司在基础设施和新产品推出方面的投资正将其定位于未来的增长,几个治疗项目的临床试验取得了显著进展。 The company's investments in infrastructure and new product launches are positioning it for future growth, with notable progress in clinical trials for several therapeutic projects.